CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for XTENT, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

XTENT, Inc.
125 Constitution Drive
Phone: (650) 475-9400p:650 475-9400 Menlo Park, CA  94025  United States Ticker: XTNT XTNT

This company ceased filing statements with the SEC on 8/27/2009.
On 8/3/2009, XTENT, Inc. held a special meeting of stockholders, at which the stockholders approved the voluntary dissolution and liquidation of the Company pursuant to a plan of complete liquidation and dissolution.
This company is no longer actively traded on any major stock exchange.

Business Summary
XTENT, Inc. is a development-stage medical device company focused on developing and commercializing drug eluting stent (DES), systems for the treatment of coronary artery disease (CAD). The DES systems are designed to enable physicians to customize both length and diameter of the stent at the site of the diseased section of the artery, or lesion, which is referred to as in situ customization. The stent systems, the Custom NX 36 and the Custom NX 60, include a modular cobalt chromium stent design, as well as a delivery system. In addition, the stents have a drug coating made of Biolimus A9, an anti-inflammatory drug, and PolyLactic Acid, a biodegradable polymer, which in combination are intended to reduce the incidence of restenosis, or renarrowing of the previously treated artery over time. The Company is developing the 36 millimeter and 60 millimeter stent systems based on the technology platform.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/200912/31/2008YesYes---

Industries
SIC Code Description
3841 Surgical and medical instruments and apparatus

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Henry A.Plain 51 10/1/2004 6/1/2002
President, Chief Executive Officer, Director Gregory D.Casciaro 52 9/1/2004 9/1/2004
Chief Financial Officer Timothy D.Kahlenberg 49 4/1/2006 4/1/2006
7 additional Officers and Directors records available in full report.

Business Names
Business Name
XTENT INC
XTENT Inc.
Xtent, Inc.
XTNT

General Information
Number of Employees: 3 (As of 6/30/2009)
Outstanding Shares: 23,501,228 (As of 7/15/2009)
Shareholders: 109
Stock Exchange: OTC
Federal Tax Id: 412047573
Fax Number: (650) 475-9401
Email Address: info@xtentinc.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023